Pharmacovigilance (PV) Software Buyer’s Guide 2026

 The pharmacovigilance software market was valued at approximately USD 2.09 billion in 2025 and is projected to reach USD 5.06 billion by 2035, growing at a CAGR of 9.24%.That growth reflects a genuine operational shift, not a commercial trend. Regulatory reporting obligations have expanded across every major jurisdiction. Case volumes have grown steadily. And the expectation that safety teams will process and submit high-quality ICSRs within tight timeframes has become firmly established across the FDA, EMA, PMDA, and MHRA.



The decision to invest in PV software is, therefore, rarely about whether to act. It is about which platform to select, how to evaluate it against your organization’s operational reality, and how to avoid the implementation pitfalls that can derail even well-planned programs.

This guide is written for decision-makers actively evaluating pharmacovigilance software platforms in 2026, and who need a structured way to separate vendor marketing from operational reality. It covers what PV software is, what features actually matter, the cloud vs on-premise question, what implementation realistically looks like, and how to build a defensible vendor shortlist.
READ FULL ARTICLE

Comments

Post a Comment

Popular posts from this blog

AI Governance in Pharmacovigilance: Building Defensible, Compliant AI Workflows for Regulatory Inspections in 2026 and Beyond

Image
  Pharmacovigilance teams aren’t being asked whether they use AI anymore — they’re being asked to prove they can control it.   That shift is what defines 2026. Regulators have moved beyond curiosity about machine learning in drug safety. They expect pharmaceutical organizations to demonstrate how AI systems are governed, validated, monitored, and audited across the safety lifecycle. The joint release of guiding principles by the FDA and EMA in early 2026 made one thing explicit:  AI governance in pharmacovigilance  must be explainable, traceable, and inspection-ready — no different from any other GxP-regulated system. For safety teams already using  AI for safety signal detection  and triage , or  adverse event case processing automation with AI , the focus has changed. It’s no longer about efficiency gains alone; now, the aim is to ensure every model decision, automation rule, and LLM-generated narrative can withstand regulatory scrutiny. Consequently...
Read more

From First Contact to Case Record: AI-Powered Pharmacovigilance Intake with AWS Connect

Image
  Drug safety hotlines have operated the same way for decades. An agent picks up a call, listens, and types what they hear into a case management system. When the call ends, they review their notes, fill in gaps, and route the case for medical review. It is a process built on human attention and manual transcription — and it has not fundamentally changed since PV call centres first came into existence. The volume of adverse event reports, however, has increased. Global drug portfolios now generate case volumes growing to 20% annually. A serious adverse event reported at 11 PM in one time zone triggers regulatory obligations that don’t wait for business hours in another. And a missed or inaccurately transcribed seriousness criterion can have consequences that reach from the case record all the way to a regulatory inspection. This is the operational context in which AWS Connect telephony for pharmacovigilance is gaining serious attention from drug safety teams. Not as a replacement f...
Read more

From Case Intake to Signal Detection: How New-Age Technologies are Reshaping Pharmacovigilance Operations – How Clinevotech is Leading Innovation

Image
  The pharmaceutical landscape is currently witnessing an unprecedented explosion in data volume. From clinical trials and electronic health records to social media and scientific literature, the sources of safety data are multiplying exponentially. For   Pharmacovigilance (PV)   teams, this presents a critical dual challenge: managing vast quantities of data while ensuring stringent regulatory compliance with global bodies such as the FDA, EMA, and MHRA. The scale of this challenge is staggering. Consider that a single adverse event can be reported through multiple channels—spontaneous reports, literature mentions, social media discussions, and clinical trial databases. Each source requires intake, assessment, coding, and signal evaluation. Traditional manual processes, which were designed for a fraction of today’s data volumes, are buckling under the pressure. Case backlogs grow, signal detection delays increase, and compliance risks mount. This is where modern technolo...
Read more